CN115590193A - 一种辅助降血糖血脂的小球藻复方保健食品及其制备方法 - Google Patents
一种辅助降血糖血脂的小球藻复方保健食品及其制备方法 Download PDFInfo
- Publication number
- CN115590193A CN115590193A CN202211301697.7A CN202211301697A CN115590193A CN 115590193 A CN115590193 A CN 115590193A CN 202211301697 A CN202211301697 A CN 202211301697A CN 115590193 A CN115590193 A CN 115590193A
- Authority
- CN
- China
- Prior art keywords
- chlorella
- powder
- extract
- filtering
- extracting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000195649 Chlorella <Chlorellales> Species 0.000 title claims abstract description 89
- 210000004369 blood Anatomy 0.000 title claims abstract description 61
- 239000008280 blood Substances 0.000 title claims abstract description 61
- 150000001875 compounds Chemical class 0.000 title claims abstract description 50
- 235000013402 health food Nutrition 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 55
- 239000000284 extract Substances 0.000 claims abstract description 53
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 38
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 38
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 33
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 33
- 235000008434 ginseng Nutrition 0.000 claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000011651 chromium Substances 0.000 claims abstract description 23
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 23
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 20
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 20
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 19
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 17
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 17
- 229940082787 spirulina Drugs 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 57
- 241000208340 Araliaceae Species 0.000 claims description 34
- 238000001914 filtration Methods 0.000 claims description 34
- 241000222336 Ganoderma Species 0.000 claims description 32
- 238000000605 extraction Methods 0.000 claims description 24
- 239000000469 ethanolic extract Substances 0.000 claims description 21
- 239000012153 distilled water Substances 0.000 claims description 15
- 238000002791 soaking Methods 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 14
- 150000002632 lipids Chemical class 0.000 abstract description 8
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 7
- 229930186217 Glycolipid Natural products 0.000 abstract description 7
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- 235000009200 high fat diet Nutrition 0.000 abstract description 7
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 6
- 210000002966 serum Anatomy 0.000 abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 239000008103 glucose Substances 0.000 abstract description 5
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract description 3
- 208000030159 metabolic disease Diseases 0.000 abstract description 3
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 3
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 238000013116 obese mouse model Methods 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 35
- 235000019197 fats Nutrition 0.000 description 27
- 239000013543 active substance Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 13
- 230000036541 health Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011573 trace mineral Substances 0.000 description 6
- 235000013619 trace mineral Nutrition 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 241000192700 Cyanobacteria Species 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 241000222341 Polyporaceae Species 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229940089161 ginsenoside Drugs 0.000 description 4
- 229930182494 ginsenoside Natural products 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000020710 ginseng extract Nutrition 0.000 description 3
- 235000021070 high sugar diet Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 241001070941 Castanea Species 0.000 description 2
- 235000014036 Castanea Nutrition 0.000 description 2
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 241000196319 Chlorophyceae Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 241000813872 Oscillatoriaceae Species 0.000 description 2
- 241000206755 Palmaria Species 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 241000222383 Polyporales Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 2
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 2
- 239000002366 mineral element Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 229920001197 polyacetylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012721 chromium Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000013224 high-fat diet-induced obese mouse Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种辅助降血糖血脂的小球藻复方保健食品及其制备方法,主要原料按重量克数计包括:小球藻200 g,灵芝100 g,人参10 g,螺旋藻粉10 g,灰树花10g,铬酵母1g。经药效学实验验证,小球藻粉末、小球藻60%醇提物和复方浓缩液能够显著改善高脂饮食诱导的肥胖小鼠糖脂代谢紊乱,特别地,能够显著降低空腹血糖、增加糖耐量;降低血清和血脂中总胆固醇、甘油三脂以及低密度脂蛋白胆固醇的水平;降低胰岛素抵抗指数;提高胰岛β细胞功能指数。
Description
技术领域
本发明属于保健食品技术领域,具体涉及一种辅助降血糖血脂的小球藻复方保健食品及其制备方法。
背景技术
随着生活水平的提高和生活节奏的改变,被称为“富贵病”的“三高症”发病率越来越高,特别是50岁以上中老年人健康的常见病,高血脂可以引起血管栓塞;高血压可以引起脑出血和脑血管破裂;高血糖可以引起糖尿病。全世界每年死于心脑血管疾病的人数高达1500万人,居各种死因首位。因此寻找开发具有降血脂血压的保健品,以辅助药物治疗,在有效的控制血糖和血脂的同时降低副作用已引起人们的关注。
小球藻属绿藻纲,小球藻科,是一种优质的绿色营养源食品,具有高蛋白、低脂肪、低糖、低热量以及维生素、矿物质元素含量丰富的优点,并且具有降血脂降血压,抗氧化,解毒,抗肿瘤增强免疫力等保健功能。灵芝又称林中灵、琼珍,是多孔菌科真菌灵芝的子实体,具有补气安神、止咳平喘、延年益寿的功效,尤其是灵芝三萜等小分子活性物质的降血脂血压的功效非常显著。灰树花,又称贝叶多孔菌、栗子蘑、莲花菌、叶状奇果菌、千佛菌、云蕈、舞茸,属非褶菌目多孔菌科植物,是一种具有抗癌功效的优秀药用菌,含有多种游离氨基酸、维生素b1、b2、c、多糖、黄酮、脂肪酸、吡咯生物碱和麦角淄醇等,可作为一种药用和食用的蘑菇可以抗糖尿病、抗癌、免疫调节活性、降血脂和降血压。人参,又名圆参、黄参、棒槌,为伞形目五加科人参属多年生草本植物,主要由人参皂甙(也称为人参总皂甙)组成,为了药理作用而分离出的植物的其他成分包括挥发油,β-艾米胺,固醇,类黄酮,肽,维生素(B1,B2,B12,泛酸,烟碱酸和生物素),脂肪,聚乙炔,酶和胆碱,一些动物实验证明人参具有广泛的药理价值,包括降血糖、抗癌、抗炎症。螺旋藻,属于蓝藻门、蓝藻纲、颤藻科、螺旋藻属,是一种古老的低等原核单细胞或多细胞水生植物,富含高质量的蛋白质(以干重计为50-70%)、γ-亚麻酸的脂肪酸、类胡萝卜素、维生素,以及多种微量元素如铁、碘、硒、锌等。目前,螺旋藻在全世界范围内已被广泛用作保健品,具有多种药理作用,如降血糖、降血脂、抗氧化、抗感染、抗癌变、免疫调节和生物调节。铬是人体所需的微量元素,在机体的糖脂代谢中发挥特殊作用,能增强胰岛素活性,控制血糖。酵母铬不仅含铬较高,还含有丰富蛋白质、核酸、糖原、脂肪、生物素、多种B族维生素、固醇和其它多种微量元素,具有降低血糖和降血脂作用。
本发明以小球藻、灵芝、灰树花、螺旋藻、人参和铬酵母为原料制备了一种小球藻复方型降血糖血脂的保健品,该产品在血糖血脂方面的效果显著由于市面上的保健单品,拥有较好的保健价值,在市场上具有广阔的开发前景。
发明内容
本发明的目的主提供一种配比简单,组方搭配合理,具有显著调节糖脂代谢紊乱、增强机体的免疫力等功效的小球藻复方保健食品。
为了实现上述目的,本发明采用如下技术方案:
一种辅助降血脂的灵芝小球藻复方保健食品及其制备方法,根据中医的“君臣佐使”理论和现代营养学知识,将小球藻、灵芝、灰树花、人参子实体原料采用磨粉、热水浸提、过滤、减压浓缩干燥得到小球藻、灵芝、灰树花和人参提取物粉末,再用螺旋藻、铬酵母为原料制备复方浓缩液,该复方浓缩液制备具有辅助降血糖血脂的灵芝小球藻复方保健食品。其主要原料配方按重量份数计包括:小球藻200 g,灵芝100 g,人参10 g,螺旋藻粉10 g,灰树花 10g,铬酵母1g。
所述的一种辅助降血脂的灵芝小球藻复方保健食品的制备方法,具体包括如下步骤:
(1) 小球藻、灵芝、人参、灰树花提取物粉末的制备:
A.将小球藻、灵芝、人参、灰树花子实体磨成细粉待用;
B.取步骤A得到的小球藻粉200 g,加入10倍重量的体积分数60%乙醇溶液,于45℃提取罐中提取1 h,经过滤得小球藻60%醇提取液和滤渣;将滤渣加入10倍重量的蒸馏水,于80 ℃提取罐中提取1 h,经过滤得小球藻水提取液和滤渣;将滤渣加入10倍重量的蒸馏水,以2wt%的比例加入复合蛋白酶,于50 ℃提取罐中提取4 h,经过滤得小球藻酶解提取液;
C.取步骤A得到的灵芝粉100 g,加入20倍重量的体积分数60%乙醇溶液,于45 ℃提取罐中提取1 h,经过滤得灵芝60%醇提取液和滤渣;将滤渣加入20倍重量的蒸馏水,于80℃提取罐中提取1 h,经过滤得灵芝水提取液;
D.取步骤A得到的灰树花粉10 g,加入20倍重量的体积分数60%乙醇溶液,于45 ℃提取罐中提取1 h,经过滤得灰树花60%醇提取液和滤渣;将滤渣加入20倍重量的蒸馏水,于80 ℃提取罐中提取1 h,经过滤得灰树花水提取液;
E.取步骤A得到的人参粉10 g,加入30倍重量的蒸馏水,于80 ℃提取罐中提取1h,经过滤得人参水提取液;
F.将B、C、D、E得到的提取液分别置于陶瓷膜过滤器中过滤处理,再于60 ℃、0.075MPa条件下浓缩,得浓缩液,经干燥得小球藻(60%醇提物、水提物、酶解物)、灵芝(60%醇提物、水提物)、灰树花(60%醇提物、水提物)和人参(水提物)提取物粉末;
(2)复方浓缩液的制备 :
将小球藻提取物粉末,灵芝提取物粉末,螺旋藻粉10 g,灰树花提取物粉末,铬酵母1 g和人参提取物粉末,于砂锅中用水浸过药材表面2cm,浸泡 15 min,煮沸后文火煎煮30 min,冷却至室温,用纱布过滤,滤液经3500 r/min 离心并浓缩至 150 mL,得复方浓缩液;
(3)小球藻复方保健食品的制备
将上述复方浓缩液制备口服液,胶囊,片剂,冲剂,固体饮料,不同剂型的营养、功能性食品。
对本发明的组方原理作详细说明 :
小球藻:小球藻属绿藻纲,小球藻科,是一种优质的绿色营养源食品,具有高蛋白、低脂肪、低糖、低热量以及维生素、矿物质元素含量丰富的优点,并且具有降血脂降血压,抗氧化,解毒,抗肿瘤增强免疫力等保健功能。
灵芝:灵芝又称林中灵、琼珍,是多孔菌科真菌灵芝的子实体。具有补气安神、止咳平喘、延年益寿。尤其是灵芝三萜等小分子活性物质的降血脂血压的功效非常显著。
灰树花,又称贝叶多孔菌、栗子蘑、莲花菌、叶状奇果菌、千佛菌、云蕈、舞茸,属非褶菌目多孔菌科植物,是一种具有抗癌功效的优秀药用菌,含有多种游离氨基酸、维生素b1、b2、c、多糖、黄酮、脂肪酸、吡咯生物碱和麦角淄醇等,可作为一种药用和食用的蘑菇可以抗糖尿病、抗癌、免疫调节活性、降血脂和降血压。
人参,又名圆参、黄参、棒槌,为伞形目五加科人参属多年生草本植物,主要由人参皂甙(也称为人参总皂甙)组成,为了药理作用而分离出的植物的其他成分包括挥发油,β-艾米胺,固醇,类黄酮,肽,维生素(B1,B2,B12,泛酸,烟碱酸和生物素),脂肪,聚乙炔,酶和胆碱,一些动物实验证明人参具有广泛的药理价值,包括降血糖、抗癌、抗炎症。
螺旋藻,属于蓝藻门、蓝藻纲、颤藻科、螺旋藻属,是一种古老的低等原核单细胞或多细胞水生植物,富含高质量的蛋白质(以干重计为50-70%)、γ-亚麻酸的脂肪酸、类胡萝卜素、维生素,以及多种微量元素如铁、碘、硒、锌等。目前,螺旋藻在全世界范围内已被广泛用作保健品,具有多种药理作用,如降血糖、降血脂、抗氧化、抗感染、抗癌变、免疫调节和生物调节。
铬是人体所需的微量元素,在机体的糖脂代谢中发挥特殊作用,能增强胰岛素活性,控制血糖。酵母铬不仅含铬较高,还含有丰富蛋白质、核酸、糖原、脂肪、生物素、多种B族维生素、固醇和其它多种微量元素,具有降低血糖和降血脂作用。
本发明的有益之处:
1.本发明全部采用天然物质为原料,可以直接辅助降血糖血脂。
2.本发明配伍科学,安全可靠,适于工业化生产。
3.本发明为一种辅助降血糖血脂的小球藻复方保健品,该产品在调节血糖血脂方面的效果显著由于市面上的保健单品,拥有较好的保健价值,在市场上具有广阔的开发前景。
附图说明
图1小球藻复方保健食品对高糖高脂饮食小鼠糖脂代谢的影响。A:肝脏总胆固醇;B:肝脏甘油三酯;C:肝脏低密度脂蛋白;D:血清总胆固醇;E:血清甘油三酯;F:血清低密度脂蛋白;G:血清高密度脂蛋白;H、I、J:空腹血糖值;K、L、M:口服糖耐量。数据表示为平均值±SD(n = 10);与K1组相比,#p<0.05,## p<0.01; 与M组相比,*p<0.05,**p<0.01。
图2小球藻复方保健食品对高糖高脂饮食小鼠胰岛功能的影响。A:胰岛素抵抗指数;B:胰岛β细胞功能指数。数据表示为平均值±SD(n = 10);与K1组相比,#p<0.05,## p<0.01; 与M组相比,*p<0.05,**p<0.01。
具体实施方式
为了使本发明所述的内容更加便于理解,下面结合具体实施方式对本发明所述的技术方案做进一步的说明,但是本发明不仅限于此。
实施例1
一种辅助降血糖血脂的小球藻复方保健口服液的制备方法的步骤为:
1、小球藻、灵芝、人参、灰树花提取物粉末的制备:
A.将小球藻、灵芝、人参、灰树花子实体磨成细粉待用;
B.取步骤A得到的小球藻粉200 g,加入10倍重量的体积分数60%乙醇溶液,于45℃提取罐中提取1 h,经过滤得小球藻60%醇提取液和滤渣;将滤渣加入10倍重量的蒸馏水,于80 ℃提取罐中提取1 h,经过滤得小球藻水提取液和滤渣;将滤渣加入10倍重量的蒸馏水,以2wt%的比例加入复合蛋白酶,于50 ℃提取罐中提取4 h,经过滤得小球藻酶解提取液。
C.取步骤A得到的灵芝粉100 g,加入20倍重量的体积分数60%乙醇溶液,于45 ℃提取罐中提取1 h,经过滤得灵芝60%醇提取液和滤渣;将滤渣加入20倍重量的蒸馏水,于80℃提取罐中提取1 h,经过滤得灵芝水提取液。
D.取步骤A得到的灰树花粉10 g,加入20倍重量的体积分数60%乙醇溶液,于45 ℃提取罐中提取1 h,经过滤得灰树花60%醇提取液和滤渣;将滤渣加入20倍重量的蒸馏水,于80 ℃提取罐中提取1 h,经过滤得灰树花水提取液。
E.取步骤A得到的人参粉10 g,加入30倍重量的蒸馏水,于80 ℃提取罐中提取1h,经过滤得人参水提取液。
F.将B、C、D、E得到的提取液分别置于陶瓷膜过滤器中过滤处理,再于40℃、0.05MPa条件下浓缩,得浓缩液,经干燥分别得到小球藻(60%醇提物、水提物、酶解物)、灵芝(60%醇提物、水提物)、灰树花(60%醇提物、水提物)和人参(水提物)提取物粉末。
2、复方浓缩液的制备:
取40 g小球藻60%醇提物于砂锅中用水浸过药材表面2 cm,浸泡 15 min,煮沸后文火煎煮 30 min,冷却至室温,用纱布过滤,滤液经3500 r/min 离心并浓缩至 150 mL,得复方浓缩液1;
按原料配比分别取25 g小球藻60%醇提物、9 g小球藻水提物和5 g小球藻酶解物粉末(小球藻全活性物质)于砂锅中用水浸过药材表面2 cm,浸泡 15 min,煮沸后文火煎煮30 min,冷却至室温,用纱布过滤,滤液经3500 r/min 离心并浓缩至 150 mL,得复方浓缩液2;
按原料配比分别取小球藻全活性物(16 g小球藻60%醇提物、5 g小球藻水提物和3g小球藻酶解物粉末),灵芝60%醇提物4 g、灵芝水提物粉末4 g(灵芝全活性物质),铬酵母1g于砂锅中用水浸过药材表面2cm,浸泡 15 min,煮沸后文火煎煮 30 min,冷却至室温,用纱布过滤,滤液经3500 r/min 离心并浓缩至 150 mL,得复方浓缩液3;
按原料配比取小球藻全活性物(16 g小球藻60%醇提物、5 g小球藻水提物和3 g小球藻酶解物粉末),灵芝全活性物质(4 g灵芝60%醇提物和4 g灵芝水提物),铬酵母1g和人参水提取物粉末3 g于砂锅中用水浸过药材表面2 cm,浸泡 15 min,煮沸后文火煎煮 30min,冷却至室温,用纱布过滤,滤液经3500 r/min 离心并浓缩至 150 mL,得复方浓缩液4;
取40 g小球藻粉末于砂锅中用水浸过药材表面2 cm,浸泡 15 min,煮沸后文火煎煮 30 min,冷却至室温,用纱布过滤,滤液经3500 r/min 离心并浓缩至 150 mL,得复方浓缩液5;
按原料配比将小球藻提取物粉末、灵芝提取物粉末、螺旋藻粉10 g、灰树花提取物粉末、铬酵母1 g和人参提取物粉末,于砂锅中用水浸过药材表面2cm,浸泡 15 min,煮沸后文火煎煮 30 min,冷却至室温,用纱布过滤,滤液经3500 r/min 离心并浓缩至 150 mL,得复方浓缩液6;
3、小球藻复方保健口服液的制备 :
A、将上述初始保健浓缩液1,2,3,4,5,6煮沸,离心去除其中的不溶物质后,加入阿斯巴甜 200ppm 和苹果酸 0.1wt%;
B、调配好的口服液趁热用盐水瓶灌装、锁盖,经水浴杀菌并检验合格后即成为产品。
动物实验
实验方法:
以符合现代人类生活方式(动物性食物为主的高脂饮食习惯)的角度出发,采用高糖高脂饲料(基础饲料67%,猪油10%,蔗糖20%,胆固醇3%)建立高脂饮食诱导的糖脂代谢紊乱小鼠模型,进行为期2个月的膳食干预喂养试验。实验设9组,包括正常对照组(K1)、高脂对照组(M)、阳性对照组(MET)和复方组(CE,CM,CGC,CGCG,CP,CGSGCG)。给予受试样品60天后,将昆明小鼠禁食不禁水12小时后,在洁净工作台中,先通过心尖取血,将血液收集在采血管中,通过自动生化分析仪及试剂盒分析血清中总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C等水平。肝脏收集在冻存管中,通过自动生化分析仪及试剂盒分析肝脏中总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)等水平。
实验结果如图1、图2所示,经小球藻复方保健品实验组(CE,CM,CGC,CGCG,CP,CGSGCG)灌胃的高脂饮食诱导糖脂代谢紊乱小鼠的血液、血脂指标与空白组与模型组相比均有变化,能够显著的降低空腹血糖、增加糖耐量,降低血清和血脂中总胆固醇、甘油三脂以及低密度脂蛋白胆固醇的水平;降低胰岛素抵抗指数;提高胰岛β细胞功能指数。
附录:小球藻复方保健品对高脂饮食诱导肥胖小鼠血液指标的影响
注:“K1”指的是空白组,灌胃生理盐水,喂正常饲料;
“M”指的是模型组,灌胃生理盐水,腹腔注射链脲佐菌素;喂高糖高脂饲料;
“MET”是指的是阳性对照组,灌胃二甲双胍,喂高糖高脂饲料;
“CE”指的是小球藻60%乙醇提取组(即复方浓缩液1),灌胃小球藻60%乙醇提取物,喂高糖高脂饲料;
“CM”指的小球藻60%乙醇提取物、水提物和酶解物(小球藻全活性物质)实验组(即复方浓缩液2),灌胃球藻60%乙醇提取物、水提物和酶解物,喂高糖高脂饲料;
“CGC”指的是小球藻全活性物质、灵芝60%乙醇提取物和水提物(灵芝全活性物质)和铬酵母实验组(即复方浓缩液3),灌胃小球藻全活性物质、灵芝全活性物质和铬酵母,喂高糖高脂饲料;
“CGCG”指的是小球藻全活性物质、灵芝全活性物质、铬酵母和人参水提物实验组(即复方浓缩液4),灌胃小球藻全活性物质、灵芝全活性物质、铬酵母和人参水提物,喂高糖高脂饲料;
“CP”指的小球藻粉末实验组(即复方浓缩液5),灌胃小球藻粉末,喂高糖高脂饲料;
“CGSGCG”指的是小球藻全活性物质、灵芝全活性物质、螺旋藻粉末、灰树花全活性物质、铬酵母、人参水提物实验组(即复方浓缩液6),灌胃小球藻全活性物质、灵芝全活性物质、螺旋藻粉末、灰树花全活性物质、铬酵母、人参水提物,喂高糖高脂饲料。
以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。
Claims (3)
1.一种辅助降血糖血脂的小球藻复方保健食品,其特征在于:所述小球藻复方保健食品的主要原料按重量份数计包括:小球藻200 g,灵芝100 g,人参10 g,螺旋藻粉10 g,灰树花 10g,铬酵母1g。
2.一种如权利要求书1所述的辅助降血糖血脂的小球藻复方保健食品的制备方法,其特征在于:将小球藻、灵芝、人参和灰树花子实体采用磨粉、热水浸提、过滤、减压浓缩干燥得到小球藻、灵芝、人参和灰树花提取物粉末,再用小球藻、灵芝、人参和灰树花提取物、以及螺旋藻和铬酵母为原料制备复方浓缩液,该复方浓缩液即为所述的辅助降血糖血脂的小球藻复方保健食品。
3.根据权利要求书2所述的制备方法,其特征在于:具体制备方法包括如下步骤:
(1)小球藻、灵芝、人参和灰树花提取物粉末的制备:
A.将小球藻、灵芝、人参、灰树花子实体磨成细粉待用;
B.取步骤A得到的小球藻粉200 g,加入10倍重量的体积分数60%乙醇溶液,于45 ℃提取罐中提取1 h,经过滤得小球藻60%醇提取液和滤渣;将滤渣加入10倍重量的蒸馏水,于80℃提取罐中提取1 h,经过滤得小球藻水提取液和滤渣;将滤渣加入10倍重量的蒸馏水,以2wt%的比例加入复合蛋白酶,于50 ℃提取罐中提取4 h,经过滤得小球藻酶解提取液;
C.取步骤A得到的灵芝粉100 g,加入20倍重量的体积分数60%乙醇溶液,于45 ℃提取罐中提取1 h,经过滤得灵芝60%醇提取液和滤渣;将滤渣加入20倍重量的蒸馏水,于80 ℃提取罐中提取1 h,经过滤得灵芝水提取液;
D.取步骤A得到的灰树花粉10 g,加入20倍重量的体积分数60%乙醇溶液,于45 ℃提取罐中提取1 h,经过滤得灰树花60%醇提取液和滤渣;将滤渣加入20倍重量的蒸馏水,于80℃提取罐中提取1 h,经过滤得灰树花水提取液;
E.取步骤A得到的人参粉10 g,加入30倍重量的蒸馏水,于80 ℃提取罐中提取1 h,经过滤得人参水提取液;
F.将B、C、D、E得到的提取液分别置于陶瓷膜过滤器中过滤处理,再于60 ℃、0.075 MPa条件下浓缩,得浓缩液,经干燥分别得到小球藻提取物粉末、灵芝提取物粉末、灰树花提取物粉末和人参提取物粉末;
(2)复方浓缩液的制备 :
将小球藻提取物粉末、灵芝提取物粉末、螺旋藻粉10 g、灰树花提取物粉末、铬酵母1 g和人参提取物粉末,于砂锅中用水浸过药材表面2cm,浸泡 15 min,煮沸后文火煎煮 30min,冷却至室温,用纱布过滤,滤液经3500 r/min 离心并浓缩至 150 mL,得复方浓缩液;
(3)小球藻复方保健食品的制备
将上述复方浓缩液制备口服液,胶囊,片剂,冲剂,固体饮料,即得到所述的小球藻复方保健食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211301697.7A CN115590193A (zh) | 2022-10-24 | 2022-10-24 | 一种辅助降血糖血脂的小球藻复方保健食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211301697.7A CN115590193A (zh) | 2022-10-24 | 2022-10-24 | 一种辅助降血糖血脂的小球藻复方保健食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115590193A true CN115590193A (zh) | 2023-01-13 |
Family
ID=84848322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211301697.7A Pending CN115590193A (zh) | 2022-10-24 | 2022-10-24 | 一种辅助降血糖血脂的小球藻复方保健食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115590193A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010037256A1 (zh) * | 2008-09-26 | 2010-04-08 | Wang Maoxiang | 降低血脂和血糖的组合物 |
KR20100070154A (ko) * | 2008-12-17 | 2010-06-25 | 동아대학교 산학협력단 | 클로렐라 열수추출물을 유효성분으로 함유하는 항당뇨 조성물 |
CN105267252A (zh) * | 2015-10-10 | 2016-01-27 | 天津天狮生物发展有限公司 | 一种综合改善高血糖人群健康状况的组合物及其制备方法 |
CN106942738A (zh) * | 2017-03-15 | 2017-07-14 | 福建农林大学 | 一种小球藻全活性物质的制备方法及其产品 |
CN106942712A (zh) * | 2017-03-15 | 2017-07-14 | 福建农林大学 | 一种辅助降血脂的灵芝小球藻复方保健食品及其制备方法 |
-
2022
- 2022-10-24 CN CN202211301697.7A patent/CN115590193A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010037256A1 (zh) * | 2008-09-26 | 2010-04-08 | Wang Maoxiang | 降低血脂和血糖的组合物 |
KR20100070154A (ko) * | 2008-12-17 | 2010-06-25 | 동아대학교 산학협력단 | 클로렐라 열수추출물을 유효성분으로 함유하는 항당뇨 조성물 |
CN105267252A (zh) * | 2015-10-10 | 2016-01-27 | 天津天狮生物发展有限公司 | 一种综合改善高血糖人群健康状况的组合物及其制备方法 |
CN106942738A (zh) * | 2017-03-15 | 2017-07-14 | 福建农林大学 | 一种小球藻全活性物质的制备方法及其产品 |
CN106942712A (zh) * | 2017-03-15 | 2017-07-14 | 福建农林大学 | 一种辅助降血脂的灵芝小球藻复方保健食品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102308988B (zh) | 一种具有增强人体免疫功能的石斛保健品 | |
CN102827750A (zh) | 一种具有提高机体免疫力及性活力的玛咖保健酒 | |
CN102488281A (zh) | 一种具有降血糖作用的新型纯植物复合浓缩饮液及其制法 | |
CN104826087A (zh) | 复合辣木多肽及其制备方法和应用 | |
CN106350458A (zh) | 一种提高姬松茸液体发酵产物产量及产物活性的方法 | |
CN103462022B (zh) | 北冬虫夏草滋补膏及其制备方法 | |
CN102634441B (zh) | 一种保健醋的制备方法 | |
CN106923337A (zh) | 一种螺旋藻全活性物质的制备方法及其应用 | |
CN103976124A (zh) | 一种葛根糖果的制备工艺 | |
CN101401829A (zh) | 一种野金柴活性提取物及其制备方法和应用 | |
CN103992876A (zh) | 一种西番莲籽油的提取方法 | |
CN101664180B (zh) | 一种具有保健功效的营养复合剂及其制备方法 | |
CN103961534A (zh) | 一种含虫草多糖生物制剂的制备方法 | |
CN102512438B (zh) | 太子参多糖在制备预防、治疗糖尿病药物和保健食品中的应用 | |
CN1861637A (zh) | 淮山药多糖制备方法及其用途 | |
CN102204936B (zh) | 一种茯苓总三萜提取物的制备方法 | |
CN113349368A (zh) | 猴头菌-人参发酵菌质酵素口服液的制备工艺及应用 | |
CN101327237A (zh) | 一种植物有效组分的组合物及其制备方法和应用 | |
CN115590193A (zh) | 一种辅助降血糖血脂的小球藻复方保健食品及其制备方法 | |
CN106265717B (zh) | 狗肝菜多糖在制备防治糖尿病药物或保健品中的应用 | |
CN109674848A (zh) | 一种甘草提取物的制备方法与用途 | |
CN103054906B (zh) | 用于解酒的蜂胶乙醇提取物、制备方法及在生产口含片中的应用 | |
CN109628265A (zh) | 一种含有总黄酮的护肝保健分子酒及其制备方法 | |
CN101278974A (zh) | 一种肉桂皂甙提取物及其制备方法和应用 | |
CN106912904B (zh) | 一种灰树花全活性物质的制备方法及其产品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |